Leadership Overview
Arcera has 4 executives leading key functions including strategy, financial oversight, legal compliance, and human capital management.
Committed to advancing global health outcomes, Arcera bridges investment, talent, and expertise to address critical healthcare challenges through a diverse portfolio of 2,000 branded medicines across 90 countries.
Committed to advancing global health outcomes, Arcera bridges investment, talent, and expertise to address critical healthcare challenges through a diverse portfolio of 2,000 branded medicines across 90 countries.
Leadership Roles at Arcera
Isabel Afonso - Chief Executive Officer
Isabel Afonso, the Chief Executive Officer at Arcera, directs the overarching strategic vision for the global life sciences organization. Overseeing operations across four continents, the Chief Executive Officer ensures the integration of 2,000 branded medicines into diverse international markets. This leadership role involves aligning the efforts of 6,500 employees with the corporate mission of improving human longevity and quality of life. By fostering sustainable growth and managing complex healthcare challenges, Isabel Afonso drives the company toward market leadership. The Chief Executive Officer maintains constant communication with the Board to refine long-term objectives and capital allocation. Through rigorous oversight of the pharmaceutical portfolio, Afonso secures the competitive positioning of the firm. Ultimately, the Chief Executive Officer guarantees that all business activities support the core goal of mitigating global health issues while maintaining operational excellence across the entire enterprise.
Hany Amin - Chief Financial Officer
Hany Amin, the Chief Financial Officer at Arcera, manages the fiscal health and capital structure of the global life sciences entity. Overseeing financial planning, reporting, and risk management, the Chief Financial Officer ensures the stability required to support operations in over 90 countries. This leadership role involves optimizing resource allocation to sustain the production and distribution of 2,000 branded medicines. By analyzing market trends and economic indicators, Hany Amin provides the data-driven insights necessary for strategic decision-making at the executive level. The Chief Financial Officer coordinates with regional leads to monitor expenditure and revenue growth across four continents. Through disciplined financial governance, Amin protects the assets of the organization while enabling investment in new therapeutic areas. Ultimately, the Chief Financial Officer maintains the fiscal integrity of the company, ensuring long-term viability and shareholder value in a competitive pharmaceutical landscape.
Amin Ben Lakhal - Chief Legal Officer
Amin Ben Lakhal, the Chief Legal Officer at Arcera, directs the global legal strategy and regulatory compliance framework for the life sciences organization. Overseeing intellectual property protection and corporate governance, the Chief Legal Officer ensures adherence to complex international pharmaceutical regulations across 90 countries. This leadership role involves mitigating legal risks associated with the development and distribution of 2,000 branded medicines. By providing counsel on mergers, acquisitions, and cross-border partnerships, Amin Ben Lakhal facilitates the expansion of the company footprint. The Chief Legal Officer collaborates with the executive team to navigate the intricate legal environments of four continents. Through proactive policy development and litigation management, Lakhal safeguards the reputation and operational continuity of the firm. Ultimately, the Chief Legal Officer maintains the highest standards of corporate ethics and legal compliance, supporting the mission to improve human life through secure and regulated pharmaceutical innovation.
Muhanna Al Nuaimi - Chief People Officer
Muhanna Al Nuaimi, the Chief People Officer at Arcera, directs the human capital strategy for the global workforce of 6,500 employees. Overseeing talent acquisition, organizational development, and employee engagement, the Chief People Officer ensures the alignment of human resources with the company mission of addressing healthcare challenges. This leadership role involves cultivating a high-performance culture across 90 countries to support the delivery of 2,000 branded medicines. By implementing comprehensive training and leadership programs, Muhanna Al Nuaimi drives professional growth and operational efficiency within the life sciences sector. The Chief People Officer coordinates with department heads to optimize workforce planning and retention strategies across four continents. Through the promotion of diversity and inclusion, Al Nuaimi strengthens the internal capabilities of the organization. Ultimately, the Chief People Officer fosters a sustainable and motivated workforce, ensuring the company maintains the expertise necessary to lead in the global pharmaceutical market.
Explore Leadership Teams in Manufacturing
Fresenius Kabi, a subsidiary of Fresenius, is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. Fresenius Kabi is headquartered in Bad Homburg, Germany with locations around the world.
Company Leadership MV
SM
CM
RT
Zydus is a global pharmaceutical company headquartered in Ahmedabad, India. Founded in 1952, the company operates manufacturing sites and research facilities across multiple states in India as well as in the United States and Brazil. Zydus specializes in developing, manufacturing, and distributing pharmaceutical products with a significant global footprint. The company maintains a strong presence in regulated markets including the United States, Europe, Latin America, and South Africa, while also serving numerous emerging markets worldwide. Zydus offers a comprehensive portfolio of pharmaceutical products and services, supported by extensive research and development capabilities.
Company Leadership RR
HS
KT
Bausch & Lomb is a global eye health company that develops, manufactures and markets healthcare products. The company's products include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. They are based in Vaughan, Ontario, Canada.
Company Leadership
DR
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership SP
CS
NB
RI
Frequently Asked Questions Regarding Arcera Top Executives and Leadership Team
